

2025 KNOWLEDGE-BASED HOME-STUDY CE FOR PHARMACISTS AND PHARMACY TECHNICIANS

Hot Off the Press...

New Recommendations for the Chronic Management of Atrial Fibrillation

<u>Speaker:</u>

Joseph Saseen, PharmD, BCPS, BCACP Associate Dean for Clinical Affairs Professor, Department of Clinical Pharmacy; Professor, Department of Family Medicine Skaggs School of Pharmacy and Pharmaceutical Science University of Colorado Anschutz Medical Campus, Aurora, CO

Learning Objectives

Upon completion of this CE activity, the participant will be able to do the following:

Learning Objectives (for pharmacists):

- Recognize the signs and symptoms of atrial fibrillation
- Describe the clinical consequences of atrial fibrillation and approaches used to diagnose
- List key recommendations from the 2023 ACC/AHA guidelines for the management of atrial fibrillation.
- Discuss pharmacotherapy used for reducing the risk of stroke and rate and rhythm control in atrial fibrillation and challenges among older patients

Learning Objectives (for pharmacy technicians):

- Review ACC/AHA guideline recommendations for the management of atrial fibrillation
- List adverse effects/warnings/precautions associated with the use of medications for rate control in atrial fibrillation
- List adverse effects/warnings/precautions associated with the use of medications for prevention of stroke in atrial fibrillation

Accreditation Information:

ACPE UAN: 0122-0000-25-017-H01-P/T CPE Credit Hours: 1.0 hour (0.1 CEU) of live CE credit Release Date: January 13, 2025 Expiration Date: January 13, 2026 Sponsorship: This program is conducted solely by Premier and has no commercial or non-commercial support or sponsorship Disclosure: Dr. Sassen reports that he is a member of the AMGEN Lipid Monitoring Board for the VESALUS and

Disclosure: Dr. Saseen reports that he is a member of the AMGEN Lipid Monitoring Board for the VESALIUS and OCEAN(a) long-term CV outcome trials. In keeping with Premier CE policies, the presentation has undergone mitigation procedures including peer review. The planners and moderators for this activity have no relevant financial relationships with ineligible companies to disclose.

For any questions, please contact Liya Davydov, Senior Director, Clinical Pharmacy Services at Liya_Davydov@premierinc.com



System Requirements to Access the Webcast: Click here to view CE webcast system requirements for the learner to complete the online activity, including the internet browser(s) supported and minimum versions of each, and the minimum memory, storage, processor, and internet

How to obtain CE credit

- 1. Log on to https://ce.continuumofcare.premierinc.com
- 2. Click on the icon that corresponds to this Home-Study CE activity
- 3. Register for that Home-Study CE activity
- 4. View and listen to the recorded activity in its entirety
- 5. Complete both the learning assessment questions and the activity evaluation.

<u>Note</u>: A passing grade of **70%** or better is required to receive CE credit. Three opportunities will be provided to successfully complete the post-test.

Once all steps above are completed, participation will be provided to CPE Monitor.



Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This CE activity is provided as a free, value-added service to Premier Continuum of Care pharmacy staff.

Speaker Bio:

Joseph Saseen is Associate Dean for Clinical Affairs and Professor of Clinical Pharmacy and a Professor of Family Medicine at the University of Colorado Anschutz Medical Campus. He is a clinical pharmacist in primary care who focuses on cardiovascular risk reduction and population health. Dr. Saseen is a Past President of the National Lipid Association (NLA), a fellow of ACCP, ASHP, APhA, and the American Heart Association, and a Master of the NLA. He is a Board-Certified Pharmacotherapy Specialist, a Board-Certified Ambulatory Care Pharmacist, and is a certified as a Clinical Lipid Specialist. He was an author of the 2018 AHA/ACC/Multisociety cholesterol management guideline, the 2022 NLA Statin Intolerance Scientific Statement, and the joint NLA/AGS Scientific Statement Treating Hypercholesterolemia in Older Primary Prevention Patients.

For any questions, please contact Liva Davydov, Senior Director, Clinical Pharmacy Services at Liva_Davydov@premierinc.com